4th Nov 2024 10:57
(Alliance News) - Futura Medical PLC on Monday said it has progressed the development of its new product pipeline, including treatments for sexual dysfunction in both men and women.
The Surrey-based sexual health products company said it has launched a further study focused on WSD4000, a potential treatment for sexual dysfunction in women, including lack of desire, arousal and lubrication.
This follows an initial proof of concept study in which Futura Medical blind-tested 16 female subjects with three gel formulations. It found that 63% of post-menopausal women reported feelings of arousal after using the preferred gel formulation.
The treatment's next stage of development will mimic a "real-world" situation in a home user study involving 60 female subjects. The company expects results in the first quarter of 2024.
"Currently, no regulatory approved topical treatment for sexual dysfunction in women is available over the counter", Futura Medical explained.
It filed a patent for WSD4000 in February, with the potential for further filings based on study outcomes. The product's development falls outside of existing commercial partner agreements for Eroxon.
Futura Medical also on Monday said it is in the process of broadening its Eroxon offering with the development of Eroxon Intense, for "strong, sustained erections".
Following an initial design study, the company has selected a preferred enhanced formulation for further consumer testing during the first half of 2025, with regulatory approval in the EU and US expected by the end of 2025.
Chief Executive Officer James Barder said: "I am delighted to announce that our highly experienced research & development team has wasted no time in focusing on developing exciting new innovation within the [over-the-counter] sexual health area. Having successfully developed, commercialised and signed world-class partnerships for our first product, Eroxon, we are excited to announce the next phase of our [new product development] roadmap.
"We have already made significant strides following the launch of Eroxon internationally, including in the US in October 2024, delivering our maiden profit in financial 2024. In a prudent manner, we are now looking to expand our range especially within the underserved clinically proven treatments for women with sexual dysfunction, whilst continuing to focus on the rollout of Eroxon across various geographical markets."
Shares in Futura Medical were up 3.1% at 38.00 pence each in London on Monday morning.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.